Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

Key Inclusion Criteria: * Be an ambulatory male or female ≥18 years of age. * Have a diagnosis of PFI. * Have current foot pain due to PFI. * Agree not to use prohibited medication, throughout the study, and not use any medication to treat PFI pain, except as permitted per the protocol. * If female, be of non-childbearing potential (history of hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or postmenopausal with no history of menstrual flow in the 12 months prior to the Screening Visit); or, if of childbearing potential, be non-pregnant, non-lactating and agree to use effective contraception when with a male partner for the duration of the study and for 28 days after any active treatment period. * Be capable of providing consent, are adequately informed, and understand the nature and risks of the study. Key Exclusion Criteria: * Has the presence of non-PFI-related nodules on the foot (for example, neurofibroma, rhabdomyosarcoma, liposarcoma, neurilemmomas, rheumatoid nodules, desmoid tumors, or malignant soft tissue lesions of the foot or ankle). * Has any musculoskeletal, neuromuscular, neurosensory, other neurological or related disorder that affects the participant's use of his or her foot and/or would impair his/her completion of study assessments as determined by the investigator. * Has any significant medical history or examination findings related to the participant's plantar nodule(s), which in the investigator's opinion, would make the participant…